Top > Search of International Patents > IMIDAZOLE COMPOUND AND MEDICINE COMPRISING SAME

IMIDAZOLE COMPOUND AND MEDICINE COMPRISING SAME

Foreign code F170009275
File No. E112P10WO
Posted date Oct 31, 2017
Country WIPO
International application number 2017JP011233
International publication number WO 2017164173
Date of international filing Mar 21, 2017
Date of international publication Sep 28, 2017
Priority data
  • P2016-056616 (Mar 22, 2016) JP
Title IMIDAZOLE COMPOUND AND MEDICINE COMPRISING SAME
Abstract Provided is a novel compound which has an excellent Aβ aggregation-inhibiting activity and is useful as a medicine. An imidazole compound represented by general formula (1) (wherein A, B and C may be the same as or different from one another and independently represent a nitrogen atom or a carbon atom; X1 and X2 may be the same as or different from each other and independently represent -CH2-, -O- or -S-; R1 and R2 may be the same as or different from each other and independently represent an aromatic hydrocarbon group that may have a substituent, or the like; R3 represents a hydrogen atom or a linear or branched alkyl group, and R4 represents a linear or branched alkyl group or a cyclic alkyl group, wherein R3 and R4 may together form a saturated heterocyclic ring in conjunction with an adjacent nitrogen atom; R5 represents a linear or branched alkyl group or a cyclic alkyl group; either one of R6 and R7 represents a hydrogen atom or an alkyl group; and the broken line in the imidazole ring means the presence of one double bond) or a salt thereof.
Scope of claims [claim1]
1. The next general formula (1)
(In formula, as for A, B and C, equality or differing, showing the nitrogen atom or the carbon atom;
X (1) and X as for (2), equality or differing, - CH [2] -, - the O- HA-S-WO showing;
R (1) and R as for (2), equality or differing, the annular alkyl group which is possible to have possessed the substituent, showing the complex cyclic basis which is possible to have possessed the aromatic hydrocarbon radical or the substituent which is possible to have possessed the substituent;
As for R (3), hydrogen atom, or direct or showing divergence chain alkyl group;
As for R (4), direct or showing divergence chain alkyl group or annular alkyl group;
R (3) and R as for (4) the nitrogen atom which it adjoins and becoming simultaneous, to be possible to form saturation complex ring;
As for R (5), direct or showing divergence chain alkyl group or annular alkyl group;
R (6) and R (7), in each case one side, showing hydrogen atom or alkyl group;
As for the broken line inside imidazole ring, double bond one shows the fact that it exists.)
So imidazole chemical compound or that salt which is shown.
[claim2]
2. Includes description above A, B and C the ring which, the following (a), (c), (d) or (e)
So the imidazole chemical compound or that salt of the claim 1 statement which is the ring which is shown.
[claim3]
3. Includes description above A, B and C the ring which, the following (c), (d) or (e)
So the claim the imidazole chemical compound or that salt of 1 which is the ring which is shown or 2 statements.
[claim4]
4. Includes description above A, B and C the ring which, the following (c)
So either of the claim 1-3 which is the ring which is shown the imidazole chemical compound or that salt of 1 section statements.
[claim5]
5. X (1) and X as for (2), equality or differing, - CH [2] - or - either of the claim 1-4 which is O-de the imidazole chemical compound or that salt of 1 section statements.
[claim6]
6. Either of the claim 1-5 where X (1) and X (2), on the one hand - is O-de, another side - CH [2] - or - is O-de the imidazole chemical compound or that salt of 1 section statements.
[claim7]
7. X (1) and X (2), in each case - either of the claim 1-6 which is O-de the imidazole chemical compound or that salt of 1 section statements.
[claim8]
8. R (1) and R (2) differing, equality or, the alkyl group of the carbon count 1-4, the alkoxy group of the carbon count 1-4, the hydroxy basis, the halogen atom, the nitro group, the 1-5 which is chosen from the amino group, the mono C [1-4] alkyl amino group, the ji C [1-4] alkyl amino group and the halogeno C [1-4] alkyl group the aromatic hydrocarbon radical of the carbon count 6-14 has been allowed to have substituted, either of the claim 1-7 which is the annular alkyl group or the complex cyclic basis of the carbon count 5-8 the imidazole chemical compound or that salt of 1 section statements.
[claim9]
9. R (3), the hydrogen atom, or the carbon count 1-12 direct or is the divergence chain alkyl group;
R (4) and R (5) differing, equality or, the hydrogen atom, the carbon count 1-12 direct or it is the divergence chain alkyl group or the annular alkyl group of the carbon count 3-8;
R (3) and R (4) the nitrogen atom which it adjoins and becoming simultaneous, may form saturation complex ring, either of the claim 1-8 the imidazole chemical compound or that salt of 1 section statements.
[claim10]
10. R (3) is the hydrogen atom, R (4) and R (5) differs equality or and either of the claim 1-9 which is the divergence chain alkyl group of the carbon count 3-8 the imidazole chemical compound or that salt of 1 section statements.
[claim11]
11. General system (1) imidazole ring in, is the next each structure,
R (6) and R (7), in each case one side the hydrogen atom or the carbon count 1-4 direct or it is the alkyl group of the divergence chain, either of the claim 1-10 the imidazole chemical compound or that salt of 1 section statements.
[claim12]
12. Either of the claim 1-11 which is chosen from the following chemical compound or that salt the imidazole chemical compound or that salt of 1 section statements.
[claim13]
13. Either of the claim 1-12 the imidazole chemical compound of 1 section statements or the amyloid I peptide cohesion inhibiter which designates that salt as the active ingredient.
[claim14]
14. Either of the claim 1-12 the medicine which contains the imidazole chemical compound or that salt of 1 section statements.
[claim15]
15. The medicine of the claim 14 statement which is the Alzheimer's disease preventive remedy.
[claim16]
16. Either of the claim 1-12 the medicine composition which contains the imidazole chemical compound or that salt of 1 section statements and the carrier which is allowed pharmacy.
[claim17]
17. Either of 1-12 for amyloid I peptide cohesion inhibiter production imidazole chemical compound of 1 section statements or use of that salt.
[claim18]
18. Either of 1-12 for Alzheimer's disease prevention remedy production imidazole chemical compound of 1 section statements or use of that salt.
[claim19]
19. Either of the 1-12 in order to obstruct amyloid I peptide cohesion the imidazole chemical compound or that salt of 1 section statements.
[claim20]
20. Either of the 1-12 in order it prevents or to remedy the Alzheimer's disease, or the imidazole chemical compound or that salt of 1 section statements.
[claim21]
21. Either of the claim 1-12 the amyloid I peptide cohesion obstruction method of featuring that the imidazole chemical compound or that salt of 1 section statements is prescribed.
[claim22]
22. Either of the claim 1-12 preventive of the Alzheimer's disease which features that the imidazole chemical compound or that salt of 1 section statements is prescribed or remedy method.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • Inventor
  • KANAI MOTOMU
  • SOMA YOHEI
  • ARAYA TAKUSHI
  • KINO RYUTO
IPC(International Patent Classification)
Reference ( R and D project ) ERATO KANAI Life Science Catalysis AREA
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close